Research

KU Eye physicians performing cutting-edge, basic, clinical and applied

research in ophthalmology and vision science

Research

 

Faculty as Principle Investigator

Dry Eye Assessment and Management (DREAM) Study  (click here for more information and enrollment details!)

Principle Investigator: John Sutphin, MD

Sub-investigator: Miranda Bishara, MD


INTACS Prescription Inserts For Keratoconus--Humanitarian Use Device

Principle Investigator: John Sutphin, MD


Faculty as Sub-Investigator

A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study to Evaluate the Efficacy and Safety of Ocrelizumab in Comparison to Interferon Beta-1a (Rebif®) in Patients with Relapsing Multiple Sclerosis - Not currently enrolling

Principle Investigator: Sharon Lynch, MD

Sub-investigator: Thomas Whittaker, MD


Multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-finding study to evaluate the efficacy, safety, and tolerability of three doses of ACT-128800, an oral S1P1 receptor agonist, administered for twenty-four weeks in patients with relapsing-remitting multiple sclerosis

Principle Investigator: Sharon Lynch, MD

Sub-investigator: Thomas Whittaker, MD


A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 1.25 mg FTY720 Administered Orally Daily Versus Placebo in Patients with Primary Progressive Multiple Sclerosis

Principle Investigator: Sharon Lynch, MD

Sub-investigator: Thomas Whittaker, MD; Miranda Bishara, MD; Dirck Dekeyser, OD


IMGN853-0401 (First-in-human study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of IMGN853 in adults with ovarian cancer and other FOLR1-positive solid tumors (IMGN-0401))

Principle Investigator: KUMC Cancer Center

Sub-Investigators:  Miranda Bishara, MD; Paul Munden, MD and W. Abraham White, MD


A randomized, double-blind, placebo-controlled study to evaluate safety, tolerability, efficacy and preliminary dose-response of BAF312 in patients with dermatomyositis

Principal Investigator:  Richard Barohn, MD

Sub-investigators:  Comprehensive Ophthalmologists


A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Activity of Ibudilast (MN-166) in Subjects with Progressive Multiple Sclerosis

Principle Investigator: Sharon Lynch, MD

Sub-investigator: OCT exam by technicnians

Last modified: Dec 22, 2014
ID=x8292